Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1

Status

Unknown 4

Sponsor Class

OTHER 113NIH 39NETWORK 7OTHER_GOV 4UNKNOWN 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Esophageal Neoplasms 1Colorectal Neoplasms 1

Interventions

Capecitabine 28apatinib 25Oxaliplatin 24Cisplatin 24tislelizumab 23Gemcitabine 23Irinotecan 19Paclitaxel 18Carboplatin 18Docetaxel 15Bevacizumab 15Fluorouracil 14Drug Therapy 13Cyclophosphamide 11pembrolizumab 10camrelizumab 10Vinorelbine 9Radiation 9S 1 (combination) 8Leucovorin 8Cetuximab 8toripalimab 7sintilimab 7Rituximab 7Erlotinib Hydrochloride 7pyrotinib 6Gefitinib 6Albumin-Bound Paclitaxel 6fludarabine 5anlotinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × OTHER_GOV × Thalidomide × Clear all
NCT06231680 2024-03-29

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Henan Cancer Hospital

Phase 2 Unknown
132 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms

NCT05266820 2022-03-18

Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer

Fujian Cancer Hospital

Phase 2 Unknown
120 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT02733380 2020-04-01

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

Henan Cancer Hospital

Phase 2 Unknown
20 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03341494 2017-11-14

EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

Fujian Cancer Hospital

Phase 2 Unknown
128 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡